Erasca, INC 8-K filings

Erasca, Inc. announced second quarter 2026 financial results and business updates, highlighting progress in its ERAS-0015 and ERAS-4001 clinical programs and a substantial capital raise.

Erasca, Inc. announced the appointment of Dr. Charles S. Fuchs as President, Research & Development, effective August 10, 2026, bringing extensive oncology and drug development expertise.

Erasca, Inc. announced the pricing of an upsized public offering of approximately $550 million of its common stock, with net proceeds expected to be around $516 million.

Erasca, Inc. announced updated preliminary Phase 1 data for its ERAS-0015 molecular glue, showing encouraging monotherapy responses and promising combination potential, alongside accelerated development plans.

Erasca, Inc. announced its first quarter 2026 financial results and provided business updates, highlighting progress in its RAS-targeting oncology pipeline and a strong cash position.

Erasca announced positive preliminary Phase 1 dose escalation data for its pan-RAS molecular glue, ERAS-0015, in patients with RAS-mutant solid tumors.

Erasca, Inc. announced a conference call to discuss preliminary Phase 1 data for ERAS-0015, but also disclosed a patent infringement and trade secret misappropriation letter from Revolution Medicines, Inc.

Erasca, Inc. has updated its guidance for the Phase 1 monotherapy data readout of its pan-RAS molecular glue ERAS-0015, now expected no later than mid-May 2026.

Erasca announced its Q4 and full year 2025 financial results, highlighted by encouraging early clinical data for ERAS-0015, a successful $259 million financing, and extended cash runway into H2 2028.

Erasca, Inc. announced the pricing of an upsized public offering of 22.5 million shares of common stock at $10.00 per share, expecting to raise approximately $211.0 million in net proceeds.

Erasca, Inc. announced preliminary unaudited cash, cash equivalents, and marketable securities of approximately $341.8 million as of December 31, 2025.

Erasca, Inc. announced significant clinical progress for its RAS-targeting franchise, including ERAS-0015 and ERAS-4001, and outlined key milestones for 2026-2027.

Erasca reports Q3 2025 financial results, highlighting a new U.S. patent for ERAS-0015, a leadership promotion, and a cash runway into H2 2028.

Erasca, Inc. reports reduced net loss and strong cash position into H2 2028, with two key oncology candidates entering Phase 1 trials.

Erasca, Inc. announced the successful election of three Class I Directors and the ratification of KPMG LLP as its independent auditor at its annual stockholders' meeting held on June 24, 2025.

Erasca announces Q1 2025 financial results, highlights progress in RAS-targeting franchise, and extends cash runway into the second half of 2028.

Erasca announces advancements in its RAS-targeting franchise, progress in the SEACRAFT-2 trial, and a robust cash position expected to fund operations into the second half of 2027.

Erasca, Inc. updated its corporate presentation to reflect business and strategic updates, including progress on its RAS/MAPK pathway-focused pipeline, ahead of the J.P. Morgan Healthcare Conference.

Erasca announced positive preliminary data from its SEACRAFT-1 trial, progress in its RAS targeting franchise, and a strong cash position to fund operations into H1 2027.

Erasca's SEACRAFT-1 Phase 1b trial shows a 40% response rate in melanoma patients with NRAS Q61X mutations using naporafenib plus trametinib, with 70% of patients remaining on treatment.

Erasca reports a transformative second quarter of 2024, marked by in-licensing new RAS-targeting therapies, initiating a pivotal Phase 3 trial, and securing significant funding.

Erasca, Inc. held its annual meeting of stockholders on June 20, 2024, where two Class III directors were elected and the appointment of KPMG LLP as the company's independent auditor was ratified.

Erasca has announced the start of a global Phase 3 trial for its drug naporafenib in combination with trametinib for patients with NRAS-mutant melanoma.

Erasca, a clinical-stage oncology company, has announced the pricing of a $160 million underwritten offering of its common stock to fund research and development.

Erasca, Inc. has entered into exclusive license agreements for two novel cancer therapies, leading to a strategic reprioritization of its pipeline and a workforce reduction of approximately 18%.

Erasca reported promising survival data for its naporafenib combination therapy in melanoma and secured a $45 million private placement, extending its cash runway into the second half of 2026.

Erasca, a clinical-stage oncology company, has successfully raised $45 million through a private placement, extending its operational runway into the second half of 2026.

Erasca announced its fourth quarter and full year 2023 financial results, highlighting key clinical and regulatory achievements for its oncology pipeline.